# Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

> **NCT00078338** · PHASE4 · COMPLETED · sponsor: **EMD Serono** · enrollment: 764 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Rebif®
- **DRUG:** Copaxone®

## Key facts

- **NCT ID:** NCT00078338
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02-16
- **Primary completion:** 2006-11-28
- **Final completion:** 2006-11-28
- **Target enrollment:** 764 (ACTUAL)
- **Last updated:** 2018-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078338, "Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00078338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*